Tag: diabetes

Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs.

📌 The essentials On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus (insulin glargine, Sanofi) developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. It is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (2021) and Rezvoglar (2022). Interchangeable designation: pharmacists may substitute Langlara for a Lantus prescription without calling the prescriber first, subject to state pharmacy laws. Approved populations: adults and pediatric patients with type 1 diabetes, and adults with type 2 diabetes. Clinical basis: a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841 comparing insulin glargine-aldy to insulin glargine in healthy adults. Important caveat: pricing and launch date have not been publicly announced. Whether Langlara improves real-world access for patients who currently ration insulin depends almost entirely on pricing and formulary decisions not yet made.

Approximately 8.4 million Americans require insulin to survive or to manage their diabetes. For many of them, affording that insulin is not straightforward. Lantus, the most prescribed basal insulin in the world, carries a list price of several hundred dollars per month without insurance. Published surveys estimate that 1 in 4 people with diabetes in the United States reports rationing or skipping doses because of cost.

On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. The approval carries an interchangeable designation, meaning pharmacists may substitute it for Lantus at the counter without contacting the prescriber first, in states that permit such substitution.

Langlara is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (insulin glargine-yfgn) in 2021 and Rezvoglar (insulin glargine-aglr) in 2022. Whether a third entry meaningfully improves access for patients depends almost entirely on pricing and formulary decisions that have not yet been publicly announced.

What Insulin Glargine Is and Why Basal Insulin Matters

Insulin glargine is a long-acting insulin analog engineered to provide steady, predictable background insulin coverage over approximately 24 hours. The body requires two types of insulin coverage: basal, which suppresses the liver’s continuous glucose output between meals and overnight, and bolus, which handles the glucose spike that follows eating. People with type 1 diabetes produce no insulin at all and require both. Many people with type 2 diabetes eventually require basal insulin when oral medications and lifestyle changes no longer provide adequate glycemic control.

Insulin glargine (Lantus) was the first long-acting analog approved to replace older NPH insulin, which had a pronounced peak effect and required twice-daily dosing in many patients. Lantus’s flat, peakless 24-hour profile allowed once-daily dosing with lower rates of nocturnal hypoglycemia. Since its original approval in 2000, it became the most widely prescribed basal insulin in the world.

Why insulin was reclassified as a biologic, and why that matters for biosimilars Until 2020, insulin in the United States was regulated as a drug under the Federal Food, Drug, and Cosmetic Act rather than as a biologic. This meant insulin could not be approved via the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), the legal framework that allows biosimilars to enter the market and compete with reference products. In March 2020, all insulin products were transitioned to biologic status under the BPCIA. This opened the regulatory pathway for true interchangeable biosimilar approvals for insulin products, with the potential for pharmacy-level substitution. Semglee became the first interchangeable insulin biosimilar in July 2021, followed by Rezvoglar, and now Langlara. The transition also means that the FDA interchangeability standard, which requires switching studies demonstrating no loss of efficacy or increase in adverse events when alternating between the biosimilar and the reference product, now applies to insulin biosimilars.

Biosimilar Versus Interchangeable: A Distinction That Matters at the Pharmacy Counter

Not all biosimilars are interchangeable, and the distinction has real consequences for how patients access the product.

	Biosimilar only	Interchangeable biosimilar
FDA standard	Highly similar to reference product; no clinically meaningful differences in safety, purity, or potency	All biosimilar standards plus: switching studies showing no greater risk than reference product when alternating
Pharmacy substitution	Cannot be substituted automatically; requires new prescription or prescriber authorization in most states	Pharmacist may substitute for the reference product without calling the prescriber, subject to state law
Patient impact	Access depends on prescriber writing specifically for the biosimilar or insurer mandating it	Patient may receive the biosimilar on a Lantus prescription without any additional action from their doctor
Langlara status	Yes	Yes, interchangeable designation granted April 29, 2026

The interchangeable designation requires manufacturers to conduct switching studies in which patients alternate between the biosimilar and the reference product at least three times, to confirm there is no loss of efficacy or increase in adverse events from switching. For Langlara, the approval was based on a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841, comparing insulin glargine-aldy to insulin glargine in healthy adults, along with the broader analytical and preclinical data package.

The Insulin Glargine Landscape: Three Interchangeable Biosimilars, One Reference Product

Product	Maker	FDA approved	Status
Lantus (insulin glargine)	Sanofi	2000	Reference product
Basaglar (insulin glargine-aglr)	Eli Lilly	2015	Biosimilar only (not interchangeable); launched 2016
Semglee (insulin glargine-yfgn)	Biocon/Viatris	2021	First interchangeable insulin biosimilar; launched at approximately $148 per 5-pack vs. Lantus approximately $340 to $520 per month
Rezvoglar (insulin glargine-aglr)	Eli Lilly	2022	Second interchangeable biosimilar; launched April 2023 at $92 per 5-pack (77% below Lantus list price)
Langlara (insulin glargine-aldy)	Lannett/Lanexa/Sunshine Lake	April 29, 2026	Third interchangeable biosimilar; pricing and launch date not yet announced

The competitive pricing history of this space is instructive. When Semglee launched as the first interchangeable biosimilar in 2021, it priced at a wholesale acquisition cost of approximately $148 per package of five prefilled pens, compared with $340 to $520 per month for Lantus without insurance. Eli Lilly’s Rezvoglar entered in April 2023 at $92 per 5-pack, setting a new low-price benchmark. Whether Langlara will compete at or below these levels has not been disclosed.

For context on how the biosimilar market is evolving in another drug class, see our post on PONLIMSI and the crowded denosumab biosimilar landscape, where 19 FDA approvals have produced only modest savings for patients due to the same rebate dynamics described below.

For related coverage of what is changing in the broader insulin landscape, see our post on Awiqli, the first once-weekly basal insulin approved for type 2 diabetes in 2026.

The Access Question: Why Regulatory Approval Is Not the Same as Affordable Access

An FDA approval of an interchangeable biosimilar is a necessary condition for improved insulin access. It is not, on its own, sufficient. The history of insulin biosimilars in the United States illustrates the gap.

Semglee launched in 2021 with a list price meaningfully below Lantus. But list prices are not what most insured patients pay: pharmacy benefit managers (PBMs) negotiate rebates with manufacturers, and those rebate arrangements often favor the originator product on formulary even when a biosimilar carries a lower list price. The result is that biosimilar insulin market penetration in the United States has grown more slowly than in Europe, where national procurement systems and institutional substitution policies have driven biosimilar adoption rates above 90% in some countries.

California’s CalRx Biosimilar Insulin Initiative offers a different model. As of January 1, 2026, CalRx-branded insulin glargine pens became available to California residents at $55 for a five-pack through a state partnership with Civica Rx and Biocon Biologics, regardless of insurance status. That price point, enabled by state procurement rather than commercial market dynamics, illustrates what becomes possible when the insulin access question is addressed as a public health problem rather than a market competition question.

For Langlara specifically, Lanexa Biologics has stated its intention to pursue broad formulary placement across all commercial channels. Whether that translates to meaningful out-of-pocket savings for the 1 in 4 diabetes patients who report difficulty affording insulin will depend on the specific list price set at launch and the formulary tier negotiations that follow.

What patients transitioning to any insulin glargine biosimilar should know No dose conversion is required when switching between interchangeable insulin glargine products. The biosimilar delivers the same clinical effect at the same dose as Lantus. Blood glucose monitoring is still recommended during any transition period, as individual insulin requirements can vary based on factors unrelated to the product switch itself. Device differences matter. Langlara is supplied as a prefilled pen. Lantus is available in both a prefilled pen and a vial. If your current regimen uses a vial and your pharmacy substitutes a prefilled pen, confirm the administration steps with your pharmacist or diabetes care team. If your pharmacist has substituted a biosimilar for Lantus, they are required by law to notify you and your prescriber of the substitution in states with such requirements. Ask your pharmacist about the specific rules in your state. If you have concerns about a substitution, you or your prescriber can request that a specific product be dispensed by noting “dispense as written” on the prescription.

Safety Profile: Consistent With the Insulin Glargine Class

As an interchangeable biosimilar, Langlara is expected to have the same clinical profile as Lantus. Warnings, precautions, and adverse reactions apply to the insulin glargine class as a whole.

Hypoglycemia: The most clinically important risk of any insulin therapy. Severe hypoglycemia can be life-threatening. Risk increases with missed meals, excessive exercise, alcohol use, renal impairment, and co-administration with other glucose-lowering agents including sulfonylureas.
Medication errors: Insulin concentration errors are a documented source of patient harm. Langlara is U-100 (100 units per mL). Never use U-100 insulin in a syringe designed for a different concentration. Do not mix insulin glargine with other insulins.
Hypokalemia: Insulin drives potassium into cells. Monitoring of potassium is important in patients at risk, including those with renal disease or on medications that lower potassium.
Hypersensitivity: Severe or life-threatening hypersensitivity reactions, including anaphylaxis, have been reported with insulin products. Discontinue and seek emergency care if systemic hypersensitivity occurs.
Thiazolidinediones (TZDs): Pioglitazone and similar drugs used alongside insulin can cause fluid retention and increase the risk of heart failure. Patients on both should be monitored for signs of fluid retention.
Injection site reactions: Lipodystrophy (skin thickening or pitting at injection sites) can develop with repeated injections at the same site. Rotate injection sites within the recommended areas (abdomen, thigh, deltoid).

What This Approval Means in Practice

Langlara’s approval adds a third interchangeable insulin glargine biosimilar to the U.S. market. The interchangeable designation is meaningful: it allows pharmacy-level substitution without a new prescription, which reduces one logistical barrier to biosimilar uptake. Whether it reduces the financial barrier depends on what Lanexa Biologics announces for pricing and formulary positioning at launch.

For patients currently on Lantus or another insulin glargine product, the most useful resources while commercial pricing evolves are the American Diabetes Association, which maintains current guidance on insulin assistance programs and state programs, and InsulinHelp.org, a nonprofit directory of insulin access resources. The JDRF also maintains updated insulin affordability resources specifically for people with type 1 diabetes.

For more on how biosimilar approvals interact with real-world access, and why regulatory clearance does not automatically translate to patient savings in the U.S. market, see our post on PONLIMSI and the denosumab biosimilar landscape.

Sources

Lannett/Lanexa/Sunshine Lake press release: Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA (insulin glargine-aldy). BioSpace. May 4, 2026.

Drugs.com approval history: Langlara (insulin glargine-aldy) FDA Approval History. drugs.com.

Drug Topics: FDA Approves Langlara as Interchangeable Biosimilar to Insulin Glargine. drugtopics.com. May 2026.

Pharmacy Times: FDA Approves New Interchangeable Biosimilar of Insulin Glargine. pharmacytimes.com. May 2026.

Endocrinology Advisor: Langlara Receives FDA Nod as Interchangeable Lantus Alternative. endocrinologyadvisor.com. May 2026.

Contemporary Pediatrics: FDA approves interchangeable insulin glargine-aldy for type 1 and type 2 diabetes. contemporarypediatrics.com. May 2026.

FDA prescribing information: LANGLARA (insulin glargine-aldy) Prescribing Information. BLA 761412. FDA.gov. 2026.

Phase 1 PK/PD study registration: NCT05248841. A Study to Assess the Pharmacokinetics and Pharmacodynamics of Insulin Glargine-ALDY Versus Insulin Glargine. ClinicalTrials.gov.

Semglee FDA approval: FDA approves Semglee, first interchangeable biosimilar insulin. FDA.gov. 2021.

Rezvoglar FDA approval: FDA approves insulin glargine-aglr (Rezvoglar). FDA.gov. 2022.

CalRx Biosimilar Insulin Initiative: CalRx. $55 per 5-pack prefilled pen. calrx.ca.gov. January 2026.

FDA interchangeable biosimilars: Biosimilar and Interchangeable Products. FDA.gov.

FDA BPCIA framework: Biosimilar Development, Review, and Approval. FDA.gov.

PBM market structure: Pharmacy Benefit Managers. PMC7748166.

Patient resources: American Diabetes Association | InsulinHelp.org | JDRF insulin affordability resources | CalRx insulin program

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. All insulin therapy decisions, including switching between products, should be made in consultation with your diabetes care provider or endocrinologist.

May 17, 2026

365 Injections a Year, or 52. Awiqli Is the First Once-Weekly Basal Insulin and the Science Behind It Is More Interesting Than the Dosing Schedule.

📌 The essentials On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae, Novo Nordisk), the first and only once-weekly basal insulin in history, for adults with type 2 diabetes. 52 injections per year instead of 365. The clinical basis: four randomized, treat-to-target ONWARDS Phase 3 trials enrolling approximately 2,900 adults with T2D. Three of the four trials showed statistically superior HbA1c reduction with icodec versus daily basal insulin. The fourth met non-inferiority. A meta-analysis across five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003). The mechanism: insulin icodec binds reversibly to albumin via fatty acid side chains, creating a circulating reservoir that releases active insulin continuously over approximately 8 days (half-life approximately 196 hours). Why the T1D indication is absent: an earlier FDA Complete Response Letter cited the higher hypoglycemia rate in ONWARDS 6 (the type 1 trial). The March 2026 approval covers type 2 diabetes only. Critical clinical consideration: icodec’s 196-hour half-life means dose adjustments take 3 to 4 weeks to reach new steady state. Titrate conservatively, no more frequently than every 1 to 2 weeks.

Basal insulin has been a cornerstone of type 2 diabetes management for decades. It works by providing a slow, steady background level of insulin that covers overnight glucose production by the liver and keeps blood sugar from rising between meals. For millions of people with type 2 diabetes who cannot achieve adequate glycemic control with oral medications alone, basal insulin is not optional. It is what keeps them safe.

But daily injections are a burden. Not a small one. A patient starting daily basal insulin at age 60 faces 365 injections per year for the rest of their life. Studies consistently show that fear of injection, injection fatigue, and the daily management burden contribute to insulin omission, dose skipping, and delayed treatment initiation, all of which translate into worse glycemic control and worse outcomes.

On March 26, 2026, the FDA approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin in history, 52 injections a year instead of 365. The clinical data behind it spans five randomized trials and approximately 4,000 patients. It shows not just non-inferiority to daily basal insulin, but in several studies, superior HbA1c reduction. Understanding how that is possible, and what the trade-offs are, requires going inside the chemistry.

How Awiqli Actually Works: The Albumin-Binding Depot Mechanism

Existing basal insulins, glargine (Lantus, Toujeo, Basaglar) and degludec (Tresiba), achieve their extended duration through different mechanisms. Glargine precipitates at physiological pH, forming microcrystals that dissolve slowly. Degludec forms multi-hexameric chains that dissociate gradually from the injection site. Both produce half-lives of 12 to 25 hours, sufficient for once-daily dosing.

Insulin icodec takes a fundamentally different approach. The molecule is engineered with two fatty acid side chains that allow it to bind reversibly to albumin, the most abundant protein in blood plasma. When injected, icodec does not just sit at the injection site waiting to dissolve. It enters the bloodstream and binds to circulating albumin, which acts as a reservoir. Only a small fraction of icodec is free and active at any given time; the rest is temporarily sequestered in the albumin-bound depot. As free icodec is cleared by the body, more is released from albumin to replace it.

The result is a half-life of approximately 196 hours, about 8 days. This is long enough that a single injection provides stable, continuous insulin coverage for an entire week, with a flat pharmacodynamic profile that avoids the peak-and-trough pattern that can contribute to hypoglycemia with shorter-acting insulins.

Why the long half-life creates a specific clinical consideration The same pharmacokinetic property that enables once-weekly dosing also means that any dose adjustment takes longer to reach a new steady state. With daily insulin, a dose increase or decrease produces a measurable effect within 1 to 2 days. With icodec’s 196-hour half-life, it takes approximately 3 to 4 weeks to reach a new steady state after a dose change. This has a practical implication for titration: icodec should be titrated conservatively, with dose adjustments made no more frequently than every 1 to 2 weeks based on fasting blood glucose. Aggressive titration, adjusting every few days as some patients do with daily insulins, risks overshoot and delayed hypoglycemia. The prescribing information provides specific titration guidance that clinicians should review carefully. Similarly, if a patient is transitioning off icodec to another insulin, the insulin effect persists for several days after the last dose. Overlap with a new insulin must be carefully managed to avoid hypoglycemia during the transition period.

Why This Is a Resubmission and Why Type 1 Diabetes Is Not on the Label

The March 2026 approval is not the first time Awiqli went through FDA review. In July 2024, the FDA issued a Complete Response Letter citing two issues: concerns about the manufacturing process, and concerns about the safety of insulin icodec specifically in patients with type 1 diabetes.

The type 1 concern is worth understanding. ONWARDS 6, the Phase 3 trial evaluating insulin icodec in T1D, showed that icodec was non-inferior to degludec for HbA1c reduction. But in T1D patients, the rate of clinically significant or severe hypoglycemia was meaningfully higher in the icodec arm than in the degludec arm. The FDA’s advisory committee voted against approval for T1D, and the agency’s concerns were reflected in the CRL.

Novo Nordisk’s response was pragmatic: rather than try to address the T1D concerns in the resubmission, which would have required additional clinical data and further delayed approval, the company resubmitted in September 2025 for the T2D indication only, where the efficacy and safety data were consistently robust. That resubmission was approved in March 2026.

Novo Nordisk has stated that it remains committed to exploring icodec for type 1 diabetes and plans to conduct a new clinical trial in this population. The T1D indication is not closed; it is deferred. For now, Awiqli is approved for adults with type 2 diabetes only.

The ONWARDS Trials: What the Clinical Evidence Shows

The FDA approval is based on four trials from the ONWARDS Phase 3a clinical program, all randomized, active-controlled, and treat-to-target in design. “Treat-to-target” means that insulin doses in both arms were titrated to achieve the same blood sugar goals, a rigorous design that tests whether the drugs perform equivalently under optimized conditions.

Trial	Population	Comparator	HbA1c reduction (icodec)	HbA1c reduction (comparator)
ONWARDS 1 (78 wk, n=984)	Insulin-naive T2D on non-insulin agents	Glargine U100 (once daily)	−1.55%	−1.35%*
ONWARDS 2 (26 wk, n=526)	T2D switching from daily basal insulin	Degludec (once daily)	−0.93%	−0.71%†
ONWARDS 3 (26 wk, n=588)	Insulin-naive T2D on non-insulin agents	Degludec (once daily)	−1.57%	−1.36%†
ONWARDS 4 (26 wk, n=582)	T2D on basal-bolus regimen	Glargine U100 (once daily)	−1.16%	−1.18% (NI met)

* Superior (p less than 0.001) vs. glargine U100. † Superior (p less than 0.003 to p less than 0.0007) vs. degludec. NI = non-inferiority. Source: Published ONWARDS trials in NEJM, Lancet, JAMA, Lancet Diabetes Endocrinology.

Three of the four trials showed statistically superior HbA1c reduction with icodec compared to daily basal insulin. The fourth (ONWARDS 4, in patients already on basal-bolus regimens) met the pre-specified non-inferiority margin. A meta-analysis across all five ONWARDS trials showed a mean incremental HbA1c benefit of 0.17% (95% CI 0.06 to 0.28; p=0.003) and an odds ratio of 1.51 (95% CI 1.14 to 1.99) for achieving HbA1c below 7% with icodec versus comparators.

ONWARDS 1 also demonstrated a secondary endpoint of superior Time in Range (blood glucose 70 to 180 mg/dL) with icodec compared to glargine U100, a clinically meaningful finding given the growing emphasis on TIR as an outcome measure alongside HbA1c. Additionally, in ONWARDS 1 and 3, a higher proportion of insulin-naive patients achieved an HbA1c target below 7% without clinically significant or severe hypoglycemia with icodec versus comparators, suggesting that the once-weekly drug can deliver better glycemic control without proportionally increasing hypoglycemia burden in this population.

Dr. Julio Rosenstock, MD, Clinical Professor at UT Southwestern Medical Center and Principal Investigator of the ONWARDS trial program, characterized the approval at the time of the FDA decision as underscoring the need for new alternative insulin options that may help patients work with their healthcare providers to determine what treatment works best for them.

The Hypoglycemia Picture: Nuanced, Not Alarming

Hypoglycemia is the most important safety consideration in any insulin therapy, and the icodec data requires careful interpretation rather than a headline summary.

In insulin-naive patients (ONWARDS 1 and 3), the picture is favorable: despite achieving better HbA1c control, icodec did not generate significantly more hypoglycemia than comparators, and more patients reached target HbA1c without experiencing level 2 or level 3 hypoglycemia.

The nuance comes in the switching studies (ONWARDS 2 and 3 for patients already on insulin). Here, numerically higher rates of clinically significant (level 2) or severe (level 3) hypoglycemia were observed with icodec compared to degludec. In ONWARDS 3, rates were 0.31 versus 0.15 events per patient-year. This difference reflects a specific pharmacokinetic challenge: when patients switch from daily to weekly insulin, there is an initial period during which the full icodec depot is being established. The prescribing information recommends initiating icodec at 20% higher than the previous total daily dose for patients switching from daily basal insulin, specifically to manage this titration period.

The clinical alert on hypoglycemia in T2D Patients treated with Awiqli tended to have a greater incidence of hypoglycemia than daily comparators in some study arms, while in insulin-naive patients the rates were comparable or favorable. The key implication is that icodec requires more careful patient selection and titration guidance when used as a switch therapy versus a treatment initiation therapy. In T2D specifically, the clinical concern about hypoglycemia is lower than in T1D: T2D patients retain some endogenous insulin secretion and have counterregulatory responses that protect against severe hypoglycemia. The T1D population, where hypoglycemia was more concerning and drove the CRL, is not included in the current U.S. approval. For T2D, the FDA and the ONWARDS investigators judged the benefit-risk profile favorable.

Practical Use: Dosing, Switching, and Missed Doses

The U-700 concentration: what this means practically

Awiqli is a U-700 formulation, 700 units per mL, compared to the U-100 (100 units per mL) that most daily basal insulins use. This higher concentration is what allows a full week’s worth of insulin to be administered in a single manageable injection volume. It means that icodec is not substitutable unit-for-unit with daily insulins: a week’s dose of icodec is roughly equivalent to 7 days of the total daily dose, not a single daily dose. Careful dose calculation is required at initiation and when switching.

Starting doses and switching guidance

Patient situation	Starting approach
Insulin-naive	Start at 70 units once weekly. Titrate based on fasting blood glucose, adjusting no more than every 2 weeks.
Switching from daily basal insulin	Start at 20% higher than previous total daily basal dose, given once weekly. This accounts for the accumulation phase.
Adding to GLP-1 or oral agents	Start at 70 units weekly (same as insulin-naive). Be alert to enhanced glucose-lowering from the combination.
Patients on basal-bolus regimens	Switch based on individual assessment; the ONWARDS 4 data supports the transition in this population.

Missed dose flexibility: a genuine practical advantage

One underappreciated benefit of icodec’s long half-life is missed-dose forgiveness. Because the drug accumulates in the albumin depot and releases continuously, a missed or shifted dose is less clinically consequential than with daily insulin. The prescribing information states that if a dose is missed, it can be administered up to 3 days (72 hours) before or after the scheduled day. After administration, resume the original once-weekly schedule. This flexibility directly addresses one of the practical frustrations of daily insulin, the anxiety around a forgotten or delayed dose.

Administration

Awiqli is administered subcutaneously once weekly on the same day each week, using the Novo Nordisk FlexTouch prefilled pen. It is available in three pen sizes: 700 units per 1 mL, 1050 units per 1.5 mL, and 2100 units per 3 mL. It must not be administered intravenously, intramuscularly, or via insulin pump, and must not be mixed with other insulin products.

Safety: What the Prescribing Information Covers

The safety profile of Awiqli is broadly consistent with the basal insulin class, with the nuances around hypoglycemia and titration already discussed above.

Common adverse reactions: hypoglycemia, injection site reactions (redness, swelling, itching), lipodystrophy (skin thickening or pitting at injection sites), pruritus, rash, peripheral edema, weight gain.

Serious risks:

Severe hypoglycemia
Serious hypersensitivity reactions including anaphylaxis, angioedema, urticaria, and swelling of face and lips
Hypokalemia (low potassium, which may affect heart rhythm)

Thiazolidinediones (TZDs): Use with pioglitazone or rosiglitazone increases the risk of fluid retention and potential heart failure exacerbation. Monitor for signs of heart failure when co-prescribing.

Acute illness and fasting: During illness or significant changes in eating, blood glucose monitoring frequency should increase and dose adjustments may be needed. The long half-life means that missed or delayed doses are tolerated, but significant metabolic stress (surgery, serious illness) requires closer glucose monitoring.

Not indicated for: ketoacidosis treatment, diabetic ketoacidosis, use via intravenous or intramuscular routes, or use with insulin infusion pumps.

Why Injection Frequency Matters More Than It Might Seem

The clinical significance of moving from daily to weekly injections goes beyond convenience. The diabetes literature on insulin adherence is consistent: injection burden is one of the leading modifiable barriers to insulin initiation and continuation. “Psychological insulin resistance,” the phenomenon in which patients delay or avoid starting insulin despite clinical need, is documented in 20 to 30% of people with T2D who are recommended insulin.

Insulin omission is also common among those already on therapy: studies estimate that 20 to 50% of patients on daily basal insulin skip doses at least occasionally, with higher rates among those with greater injection frequency or complex regimens. Each omitted dose represents a period of inadequate glycemic coverage. Sustained omission accelerates the development of diabetes complications.

Once-weekly dosing does not eliminate these barriers, but it substantially reduces the number of opportunities for omission and lowers the daily psychological overhead of managing insulin therapy. Whether this translates into measurably better real-world outcomes beyond what the controlled trials demonstrated will only be known from post-marketing evidence. But the mechanistic argument is sound.

Availability and Global Status

Novo Nordisk has indicated Awiqli will be available at U.S. pharmacies in the second half of 2026. The drug has already been approved in the European Union, Canada, Australia, Japan, Switzerland, and more than a dozen other countries, in many of those markets for both type 1 and type 2 diabetes. The U.S. approval is limited to type 2 diabetes.

Pricing and formulary coverage have not been announced for the U.S. market at time of writing. Patients and clinicians should check with their insurance provider and Novo Nordisk’s patient support resources as the launch approaches. For patients on insulin experiencing cost barriers, the Novo Nordisk patient assistance program and the NeedyMeds database are useful starting points.

For related HED coverage on diabetes treatment advances and access, see our posts on the FDA approval of the first generic dapagliflozin tablets and the approval of Foundayo (orforglipron), the first oral GLP-1 pill for weight management without food or water restrictions.

Sources

FDA approval and Novo Nordisk press release: FDA approves Novo Nordisk’s Awiqli (insulin icodec-abae), the first and only once-weekly basal insulin treatment for adults with T2D. March 26, 2026. prnewswire.com.

HCPLive coverage: FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes. hcplive.com. March 2026.

Patient Care Online coverage: FDA Approves Once-Weekly Basal Insulin for Adults With Type 2 Diabetes. patientcareonline.com. March 2026.

Consultant360: FDA Approves Awiqli (Insulin Icodec-Abae) as Once-Weekly Basal Insulin. consultant360.com. March 2026.

ONWARDS 1 (NEJM): Rosenstock J et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. NEJM. 2023;389(16):1533. doi:10.1056/NEJMoa2310221

ONWARDS 2 (Lancet Diabetes Endocrinol): Philis-Tsimikas A et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in basal insulin-treated T2D (ONWARDS 2). Lancet Diabetes Endocrinol. 2023.

ONWARDS 3 (JAMA): Lingvay I et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive T2D: ONWARDS 3. JAMA. 2023;330(3):228-237.

ONWARDS 4 (Lancet): Mathieu C et al. Switching to once-weekly icodec vs once-daily glargine U100 in basal-bolus insulin-treated T2D (ONWARDS 4). Lancet. 2023.

ONWARDS 1 trial registration: NCT04508660. ClinicalTrials.gov.

ONWARDS 2 trial registration: NCT04771052. ClinicalTrials.gov.